In human nasopharyngeal carcinoma cells (NPC-39, HONE-1, NPC-BM), EGCG treatment significantly lowered the expression and activity of MMP-2 and reduced the motility and invasion potential of tumor cells by half. This evidence concerns the gene MMP2 and nasopharyngeal carcinoma.